News: CYP Cynata Therapeutics seeks trading halt, page-104

I've had another look at the results from Mesoblasts GVHD trial

Key results in the 241 children with steroid-refractory aGVHD were:

• An overall response rate of 65% was seen at day 28 after treatment with MSC-100-IV
• A response rate of 81% was seen when MSC-100-IV was used as front-line therapy following steroid failure
• In patients with gastrointestinal and liver disease, who have the highest mortality risk, overall response rates were 65% and 62% respectively
• Children who achieved overall response at day 28 had significantly improved survival (82% vs 39%, log rank p-value <0.0001)
• Extending therapy beyond day 28 in children who had not achieved an overall response but had some improvement at day 28 resulted in significantly improved survival (72% vs 18%, log rank p-value 0.003).

This is very promising considering our technology is consistent in quality and arguably more potent. Not the mention the fact that the cost of Cymerus is likely to be several times cheaper than donor-derived MSCs products.

@pfeifer1982 - do you happen to know the approx cost of Cymerus vs donor-derived products?

300-500mill MC...... much more if we can all stick together and fight off such a low ball take over bid from Fujifilm.

Luv ya Philby....